新冠病毒感染的恢复期血浆疗法：来自严重急性呼吸综合征冠状病毒、中东呼吸综合征冠状病毒和甲型H1N1流感感染的经验教训
Convalescent Plasma Therapy for COVID-19: Lessons from SARS-CoV, MERS-CoV, and H1N1 Infection.
作者信息
Hosseini Parastoo, Rahimi Hakimeh, Najafabadi Mahsa Mohammadi, Ghorbani Atousa, Najafabadi Shima Karbasi, Faridzadeh Arezoo, Arabpour Javad, Khormali Ehsan, Deravi Niloofar
机构信息
Department of Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
出版信息
Acta Med Indones. 2021 Jan;53(1):86-95.
The global widespread mortality after the emergence of SARS-CoV-2 infection in China, has become a critical concern all around the world. Convalescent plasma (CP) therapy is one of the methods elevating the survival rate for COVID-19 infection cases. This technique, as a practicable therapy, was used in previous viral outbreaks including influenza, SARS and MERS. In CP therapy, the blood plasma is collected from persons rehabilitated from that specific infection in order to develop a passive immunity in other patients. Therefore, this review aimed to point out the role of CP therapy in aforementioned viral infections and illustrate different factors influencing the efficacy of CP therapy.
在中国出现新型冠状病毒2（SARS-CoV-2）感染后全球范围内广泛的死亡情况，已成为全世界的一个关键关注点。康复期血浆（CP）疗法是提高新型冠状病毒肺炎（COVID-19）感染病例存活率的方法之一。这项技术作为一种可行的疗法，曾用于包括流感、严重急性呼吸综合征（SARS）和中东呼吸综合征（MERS）在内的既往病毒爆发。在CP疗法中，血浆是从特定感染康复者身上采集的，以便在其他患者中产生被动免疫。因此，本综述旨在指出CP疗法在上述病毒感染中的作用，并阐明影响CP疗法疗效的不同因素。
Zotero 插件